Canada markets close in 21 minutes

Biomerica, Inc. (BMRA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.9000+0.1500 (+4.00%)
As of 03:33PM EDT. Market open.

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • B
    I am so tired of BMRA doing nothing all day. Can you move??? I have been reading for a month now and the stocks there actually go!
  • Z
    I love starting my day with the daily emails from They equip me with what I need to make wiser investment decisions!
  • d
    How is company not bankrupt yet? What a loser #$%$ this company is. Good for nothing but shorting. Come on go to zero
  • G
    "After several years of extensive development, testing, validation and clinical trials of our patented InFoods technology platform, we’re excited to now be launching the InFoods IBS test. We expect to begin generating revenues before the end of calendar year 2022."

    Knocking on the door to a positive cash flow and upside stock price.
  • R
    crushed earnings
  • J
    Y’all ready fo this???
  • S
    bought some today at around 4 bucks ,IBS results expected during this month ,positive data could push this low floater to 10 dollars . last year this stock went from $5 to $23+ within days so it could happen again .
    "Mr. Irani continued, “Finally, I am pleased to announce that data analysis is underway for our InFoods IBS clinical trial. We believe we’re on track to receive and announce top line results in January, 2022.”"
  • F
    With two subsidiaries in Mexico and Europe, Biomerica, Inc. is an entity incorporated in Delaware. The company manufactures and develops products, which help detect chronic diseases.

    In my opinion, the information released on June 16, 2020 about the development of a new test for COVID-19 made the share price creep up.

    I would actually expect additional share price increases because the company could receive the CE mark to sell the test outside the United States.

    The upside potential is massive on this name. With a share count of 11.31 million and 2.5% of the COVID-19 market, I would say that the share price could go to $25-$30.

    I am not really worried about the company’s total liabilities because the asset/liability ratio is equal to 2.3x.
    With two subsidiaries in Mexico and Europe, Biomerica, Inc. is an entity incorporated in Delaware.
    With two subsidiaries in Mexico and Europe, Biomerica, Inc. is an entity incorporated in Delaware.
  • T
    For a tiny company, these guys are really outperforming.
    This new comfortable nasal swab that can be used in, for example, offices and schools. No lab equipment. If it's for real, is easily worth today's market cap.
    Ditto upcoming h pylori test.
    IBS/InFoods would be in a totally different league.
  • D
    Has anyone paid attention to this part of their 10-Q? Focus on March 20.

    On March 17, 2020, the Company announced it had commenced shipping initial samples of its COVID-19 IgG/IgM Rapid Test (qualitative membrane-based immunoassay for the detection of IgG and IgM antibodies to SARS-CoV-2 in whole blood or serum) to countries outside the US for evaluation. The test is a finger prick blood test that the Company expects will show results in approximately 10 minutes and can be performed by trained professionals at any location, including airports, schools, work, pharmacies and doctors’ offices. The evaluation test kits have been requested by Ministries of Health in multiple countries through our distribution partners who are working with their government agencies to assess the tests and forecast demand. In addition, the Company has begun the application process with the FDA under the COVID-19 Emergency Use Authorization aimed at the possible clearance and eventual use of the test in the US.

    On March 20, 2020, the Company filed a prospectus supplement to the base prospectus dated July 20, 2017 for purposes of raising up to $12,500,000 from time to time pursuant to the terms of the At Market Issuance Agreement. The Company has no obligation to sell any of the Placement Shares under the At Market Issuance Sales Agreement, and may at any time suspend offers under the At Market Issuance Sales Agreement or terminate the At Market Issuance Sales Agreement. The Company intends to use the net proceeds from this offering for general corporate purposes, including, without limitation, sales and marketing activities, clinical studies and product development, making acquisitions of assets, businesses, companies or securities, capital expenditures, and for working capital needs.

    Subsequent to February 29, 2020 and through April 14, 2020, the Company sold 716,335 shares of common stock through the At Market Issuance Sales Agreement. Net proceeds to the Company were approximately $5,391,000.


    SO, I HATE TO SAY I WAS WRONG, BUT I'M A BIG ENOUGH MAN TO ADMIT IT. "Subsequent to Feb. 29" and "through April 14" includes from 3/17 to 3/20, the big pop. This to me does in fact look like a pump and dump. And play close attention to the description on the FDA site of the "device" registration. The "Device" was given a "proprietary name" that refers to Covid 19. So, what it seems to me that we have here is a company that shipped just the literal plastic box. Nothing in the box to test for Covid 19. You could put the
    label "generic serology test kit" or "SARS test kit" or whatever you want to call it as the "propreitary name."
    And why would you license from Mt. Sinai AFTER you supposedly shipped it already back in March?

    I am not happy.
  • D
    Biomerica’s Chairman and Chief Executive Officer Zack Irani stated, “We are very encouraged by the heightened demand we’re seeing for our products; particularly for our COVID-related testing products. As the virus continues to present new variants, we anticipate demand for these tests as well as our at-home tests for other diseases to remain strong. We are also seeing increased interest and demand across our other product lines ».

    I’m all in at this point!
  • M
    After the initial shock, I checked the internet and discovered that Biomerica filled with SEC today Form S-3 (7/20) “shelf” registration for 571,429 shares of BMRA common stock for total aggregate offering of $90 million ($10.83 per share). They used a term "up to", so Biomerica might not offer all of its 571,429 new shares. Good news-- Biomerica needs more capital for its expanding business. Bad news-- we are diluting shares, we have larger float now.
    Overall-- in my opinion, market overreacted today. TSLA did the same thing and price went up (I guess TSLA is not BMRA). But, I am not selling my shares. I am waiting for the FDA EUA news. Biomerica fundamentals remain the same. I am waiting for a pop tomorrow- we should recover some ground.
    Tomorrow will be an interesting day.
  • J
    From estimated revenue, it seems the analysts did not expect the antibody will be approved.
  • B
    I think guys, there is preference towards big companies in approving these tests. Its understandable that they can scale up production a lot as well.